Evidence map›Paper›PMID 40465540›Full record

ArticleEndocrine connections2025

Retinoid X receptor γ regulates epithelial-mesenchymal transition and tumor immune infiltration in papillary thyroid cancer tumorigenesis: an experimental and in silico study.

Pihong Li, Wei Zhang, Qiaolin Wu, Xiaohua Zhang, Zhouci Zheng

Abstract read
In one paragraph

Article in Endocrine connections, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. DNA Methylation-Based Risk Stratification and Classification of Pediatric Thyroid Carcinoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026
    Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Pihong Li
Wei Zhang
Qiaolin Wu
Xiaohua Zhang

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: This study aimed to elucidate the functional role and underlying molecular mechanisms of retinoid X receptor γ (RXRG) in the pathogenesis of papillary thyroid carcinoma (PTC). Methods: We analyzed RNA-seq data from The Cancer Genome Atlas database, ONCOMINE database, and Human Protein Atlas. RXRG expression was validated in 47 matched PTC-normal tissue pairs using real-time reverse transcription-polymerase chain reaction. Functional characterization was performed through loss- and gain-of-function experiments, complemented by flow cytometry analysis. Bioinformatics approaches were employed to investigate RXRG's role in tumor immune infiltration. Results: RXRG was significantly upregulated in PTC (P < 0.001). Elevated RXRG expression correlated with aggressive clinicopathological features, including lymph node metastasis (P = 0.041), advanced tumor stage (P = 0.035), BRAFV600E mutation (P < 0.001), and increase in tumor size (P = 0.011). Functional assays revealed that RXRG knockdown suppressed cell proliferation, colony formation, and migration capacity, whereas its overexpression promoted these oncogenic phenotypes. Mechanistically, RXRG regulated epithelial-mesenchymal transition (EMT) through modulation of E-cadherin, N-cadherin, vimentin, and key transcription factors (Snail and Slug). Furthermore, RXRG expression considerably influenced tumor immune infiltration patterns, particularly affecting eosinophils, NK cells, and B cells. Conclusion: Our study identifies RXRG as a novel oncogenic driver in PTC that promotes tumor progression through EMT regulation and immune microenvironment modulation.

Indexed as

epithelial–mesenchymal transitionimmune infiltrationlymph node metastasispapillary thyroid cancerRXRG

Identifiers

PMID40465540
PMCPMC12177880

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.